Bioiberica has received certification of its CSR management system as aligned with the United Nations Sustainable Development Goals.
Bioiberica, a global life sciences company, has received certification of its corporate social responsibility (CSR) management system as being aligned with the United Nations (UN) Sustainable Development Goals (SDGs), the company revealed in a July 27, 2021 press release.
The certification was awarded to Bioiberica after an audit process by Bureau Veritas, which highlighted strong alignment of the company’s CSR with 6 out of the 17 SDGs defined by the UN. As a result, Bioiberica has become the first Spanish pharmaceutical company to be awarded such a certification and has reaffirmed its position as committed to environmental, social, and economic sustainability.
“Bioiberica is firmly committed to sustainability and the circular economy model,” said Luis Solera, Bioiberica’s CEO, in the press release. “With this comes the responsibility of constantly working to improve the health of people, animals, and plants, and promoting a coherent ecological transition that contributes to creating a healthier planet. The recognition of the CSR management system reinforces our determination to continue working towards a better future.”
“By achieving certification of its CSR Management System aligned with the SDGs, Bioiberica takes a further step in its crucial commitment to sustainability,” added Bertrand Martin, executive president of Bureau Veritas Spain and Portugal, in the press release. “We’re very proud to have certified a company whose commitment is to improve global health and wellbeing, and working with companies like Bioiberica reinforces our desire to contribute to a more responsible economy.”
Source: Bioiberica
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.